WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinsons disease
, , ,
We support men across Broward, Miami-Dade, and Palm Beach including Fort Lauderdale, Miami, Miami Beach, Hollywood, Aventura, Boca Raton, Delray Beach, and West Palm Beach with in-clinic visits and eligible telehealth follow-ups
And we have a rigorous model-based meta-analysis placing retatrutide in the context of the incretin-based therapies across 55 trials and 16,000 patients
The trial: 2,912 people, 24 weeks, LDL down up to 60%, side effects matched placebo
You can take it with other medications without concern for interactions or meal timing